Mark Bodmer
Chief Executive Officer, Nucleome Therapeutics
Drug discovery has a human biology problem. We have the capability to read the genome, yet we struggle to understand which genetic changes cause disease, in which cells, and through which molecular mechanisms.
Many diseases are associated with genetic variation within the non-coding genome. These variants regulate gene expression through interactions that cannot be understood from DNA sequence alone. They promise significant insights into human disease, but translating these signals into drug targets remains one of genomics’ hardest challenges. Nucleome believes it has the solution.
Technology links genetics to disease
Nucleome’s Micro Capture-C (MCC) technology maps interactions between regulatory DNA and genes at unprecedented resolution and scale. Combined with AI, machine learning and computational genetics, it connects non-coding variants to the genes and cell types in which they exert their effects, providing the missing link between human genetics and molecular drivers of disease.
This approach generates Nucleome Genetic Scores, combining experimental and computational outputs, for thousands of variant-target-disease combinations in inflammatory diseases. Retrospective clinical trial analysis indicates that targets with high scores had a substantially greater probability of successful drug development.
This approach has generated Nucleome Genetic Scores,
combining experimental and computational outputs,
for thousands of variant-target-disease combinations
Targeting non-coding genome for medicine
Nucleome is now putting this discovery platform to work to build an inflammatory disease pipeline from first-in-class targets. Its lead programme, NTP464, is a monoclonal antibody agonist designed to activate a master checkpoint involved in resolving inflammation, rather than simply suppressing immune responses. NTP464 is in IND-enabling studies ahead of CTA/IND submission in 2027.
Nucleome’s ambition is to make the non-coding genome actionable by connecting human genetics to causal biology to develop medicines that address the mechanisms of disease, rather than its symptoms.
